| Name | Title | Contact Details |
|---|
TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
Diana Plants Sciences (Diana Group) is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx`s leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film.